Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 10,499 matching trials from the live ClinicalTrials.gov search.
Filters: Active, not recruiting Clear all
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

NCT02319837
View directory record Official record
Conditions
Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions
Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
77
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Phase 1 Interventional

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

NCT04690595
View directory record Official record
Conditions
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Interventions
BAFFR-CAR T cells
Biological
Lead sponsor
PeproMene Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Phase 3 Interventional

Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

NCT04794101
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
Genetic: AAV5-hRKp.RPGR Intermediate Dose, Genetic: AAV5-hRKp.RPGR Low Dose
Biological
Lead sponsor
MeiraGTx Ocular UK Ltd
Industry
Eligibility
3 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Not applicable Interventional

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy

NCT06055881
View directory record Official record
Conditions
Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Cancer
Interventions
Biospecimen Collection, Surveys, Stereotactic Body Radiation Therapy (SBRT), Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Phase 2 Interventional Results available

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

NCT03698994
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Wilms Tumor
Interventions
Pharmacokinetic Study, Ulixertinib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
105
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Phase 2 Interventional

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

NCT05681039
View directory record Official record
Conditions
Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Interventions
Tiragolumab, Atezolizumab, Standard of Care, Questionnaires, Cisplatin, Carboplatin
Drug · Behavioral · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting No phase listed Observational

Hypothalamic Amenorrhea as a Fertility Status Marker for Cardiovascular Health (ARCH)

NCT05629377
View directory record Official record
Conditions
Hypothalamic Amenorrhea
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Phase 2 Interventional Results available

Hypofractionated Radiotherapy for Soft Tissue Sarcomas

NCT03972930
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Hypofractionated Radiotherapy
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

NCT05972551
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Romosozumab, Bisphosphonate
Drug
Lead sponsor
Amgen
Industry
Eligibility
5 Years to 17 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Adipocyte-Derived Extracellular Vesicles, Weight Loss, and Endothelial Function

NCT06776081
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Weight loss without pharmacotherapy
Other
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
40 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Phase 3 Interventional

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06962280
View directory record Official record
Conditions
Type 1 Diabetes, Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
18
States / cities
Bonita, California • Escondido, California • Newport Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

A Behavioral Activation Prenatal and Postpartum Intervention for Depressed Pregnant Smokers

NCT05044546
View directory record Official record
Conditions
Depression, Tobacco Use Disorder
Interventions
Behavioral Activation Therapy, Discussion, Health Education, Questionnaire Administration, Tobacco Cessation Counseling
Behavioral · Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Phase 2 Interventional Results available

KRDI in Transplant-Eligible MM

NCT04430894
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Isatuximab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Phase 1 Interventional

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

NCT05484622
View directory record Official record
Conditions
Astrocytoma, Oligodendroglioma
Interventions
Vorasidenib, Pembrolizumab
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Not applicable Interventional

Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

NCT02661451
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
SAPIEN 3 THV, Optimal Heart Failure Therapy
Device · Biological
Lead sponsor
Cardiovascular Research Foundation, New York
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
46
States / cities
Chandler, Arizona • La Jolla, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

NCT01983410
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
The risk assessment questionnaire, Blood specimens, tumor tissue samples will be requested
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
10
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Phase 1 Interventional

Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in PAH.

NCT07751120
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, MTT with placebo + placebo supplementation.
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Phase 2 Interventional

A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

NCT01594723
View directory record Official record
Conditions
Neoplasms, Hematologic
Interventions
120 mg LY2784544
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
23
States / cities
Rogers, Arkansas • Burbank, California • Norwalk, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant

NCT05695196
View directory record Official record
Conditions
Staphylococcus Aureus, Microbial Colonization, Neonatal Infection
Interventions
nasal microbiota transplant (NMT), Placebo
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
Up to 60 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Phase 2 Interventional

Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants

NCT05364762
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Tacrolimus
Drug · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Not applicable Interventional

AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

NCT03732794
View directory record Official record
Conditions
Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
Interventions
AtriCure CryoICE & AtriClip LAA Exclusion
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
15
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

NCT04557956
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Interventions
Biopsy Procedure, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Tazemetostat Hydrobromide, Trametinib Dimethyl Sulfoxide
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
17
States / cities
Aventura, Florida • Coral Gables, Florida • Deerfield Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting No phase listed Observational

Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)

NCT05607810
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
ADVM-022
Genetic
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
6
States / cities
Beverly Hills, California • Reno, Nevada • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 5, 2026, 9:07 AM EST
Active, not recruiting Not applicable Interventional

Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study

NCT04993313
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Breast Carcinoma
Interventions
Counseling, Educational Intervention, Questionnaire
Other · Behavioral
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 5, 2026, 9:07 AM EST